Department of Orthopedics, Konya Beyşehir State Hospital, Konya, Turkey
Turk J Med Sci. 2020 Aug 26;50(5):1330-1336. doi: 10.3906/sag-1809-108.
BACKGROUND/AIM: This study aims to identify the role of synovial fluid levels of a disintegrin and metalloproteinase with thrombospondin motifs 9 (ADAMTS9) and a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) for the prediction of intraarticular steroid injection success in knee osteoarthritis (OA).
A total of eighty-four advanced stage knee OA patients (42 with stage 3 OA and 42 with stage 4 OA) were enrolled in the study. Baseline and posttreatment outcomes were determined using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pretreatment synovial fluid ADAMTS9 and ADAMTS4 levels were measured by enzyme linked immunosorbent assay (ELISA). ‘’Total WOMAC score regression of 18% and above’’ was taken as a minimal clinically important difference (MCID) to indicate improvement. Determining the best predictors of intraarticular steroid injection success in both groups was evaluated by multiple logistic regression analyses.
Synovial fluid ADAMTS9 levels were significantly lower in the stage 4 OA group when compared with the stage 3 group. The level of synovial fluid ADAMTS9 was statistically significantly lower in the WOMAC score percent change ≥18% than the WOMAC score percent change <18% group in Stage 3 OA group (P = 0.026). Decreasing synovial fluid ADAMTS9 levels (odds ratio (OR): 0.625, 95% confidence interval (CI): 0.437–0.893) were found to be predictive for the WOMAC score percent change ≥18 in all OA patients (P = 0.010). Decreasing ADAMTS9 levels in synovial fluid (OR: 0.602; 95% CI = 0.372–0.974) were predictive for MCID in stage 3 OA patients (P = 0.039).
The lower levels of ADAMTS9 in synovial fluid may be used in conjunction with high WOMAC scores in the prediction of intraarticular steroid injection success and advanced stage knee OA patients.
背景/目的:本研究旨在确定滑液中解整合素金属蛋白酶 9(ADAMTS9)和解整合素金属蛋白酶与血小板反应蛋白 4(ADAMTS4)的水平在预测膝关节骨关节炎(OA)关节内类固醇注射成功中的作用。
共纳入 84 例晚期膝关节 OA 患者(3 期 42 例,4 期 42 例)。使用西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评估基线和治疗后结果。通过酶联免疫吸附试验(ELISA)测量滑液中 ADAMTS9 和 ADAMTS4 的水平。将“总 WOMAC 评分改善 18%以上”作为最小临床重要差异(MCID)以表示改善。通过多元逻辑回归分析评估两组中关节内类固醇注射成功的最佳预测因素。
与 3 期 OA 组相比,4 期 OA 组滑液 ADAMTS9 水平显著降低。在 3 期 OA 组中,滑液 ADAMTS9 水平在 WOMAC 评分改善≥18%组明显低于 WOMAC 评分改善<18%组(P=0.026)。滑液 ADAMTS9 水平降低(比值比(OR):0.625,95%置信区间(CI):0.437-0.893)被发现可预测所有 OA 患者的 WOMAC 评分改善≥18%(P=0.010)。滑液中 ADAMTS9 水平降低(OR:0.602;95%CI=0.372-0.974)可预测 3 期 OA 患者的 MCID(P=0.039)。
滑液中 ADAMTS9 水平较低可能与高 WOMAC 评分一起用于预测关节内类固醇注射成功和晚期膝关节 OA 患者。